CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
1. AstraZeneca plans to delist ADRs from Nasdaq, listing on NYSE instead. 2. This move aims to attract global investors and improve liquidity. 3. Shares rose 0.8% following the announcement, signaling investor optimism. 4. CEO Pascal Soriot may consider full US listing due to UK frustrations. 5. UK government should act to prevent further corporate defections abroad.